The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Xerostomia (Dry Mouth Disease) Therapeutics Market Research Report 2025
Synopsis
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global Xerostomia (Dry Mouth Disease) Therapeutics market was valued at US$ 554.2 million in 2023 and is anticipated to reach US$ 673.7 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Xerostomia (Dry Mouth Disease) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Xerostomia (Dry Mouth Disease) Therapeutics.
Report Scope
The Xerostomia (Dry Mouth Disease) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Xerostomia (Dry Mouth Disease) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Xerostomia (Dry Mouth Disease) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Segment by Type
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Xerostomia (Dry Mouth Disease) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global Xerostomia (Dry Mouth Disease) Therapeutics market was valued at US$ 554.2 million in 2023 and is anticipated to reach US$ 673.7 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Xerostomia (Dry Mouth Disease) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Xerostomia (Dry Mouth Disease) Therapeutics.
Report Scope
The Xerostomia (Dry Mouth Disease) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Xerostomia (Dry Mouth Disease) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Xerostomia (Dry Mouth Disease) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Segment by Type
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Xerostomia (Dry Mouth Disease) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Artificial Saliva
1.2.3 Salivary Stimulants
1.2.4 Saliva Substitutes
1.2.5 Drugs
1.2.6 Salivary Pens
1.2.7 Others
1.3 Market by Application
1.3.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Perspective (2019-2030)
2.2 Xerostomia (Dry Mouth Disease) Therapeutics Growth Trends by Region
2.2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Xerostomia (Dry Mouth Disease) Therapeutics Market Dynamics
2.3.1 Xerostomia (Dry Mouth Disease) Therapeutics Industry Trends
2.3.2 Xerostomia (Dry Mouth Disease) Therapeutics Market Drivers
2.3.3 Xerostomia (Dry Mouth Disease) Therapeutics Market Challenges
2.3.4 Xerostomia (Dry Mouth Disease) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Xerostomia (Dry Mouth Disease) Therapeutics Players by Revenue
3.1.1 Global Top Xerostomia (Dry Mouth Disease) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Xerostomia (Dry Mouth Disease) Therapeutics Revenue
3.4 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Concentration Ratio
3.4.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Xerostomia (Dry Mouth Disease) Therapeutics Revenue in 2023
3.5 Xerostomia (Dry Mouth Disease) Therapeutics Key Players Head office and Area Served
3.6 Key Players Xerostomia (Dry Mouth Disease) Therapeutics Product Solution and Service
3.7 Date of Enter into Xerostomia (Dry Mouth Disease) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Xerostomia (Dry Mouth Disease) Therapeutics Breakdown Data by Type
4.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Xerostomia (Dry Mouth Disease) Therapeutics Breakdown Data by Application
5.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2019-2030)
6.2 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024)
6.4 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2019-2030)
7.2 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2019-2030)
9.2 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acacia Pharma
11.1.1 Acacia Pharma Company Detail
11.1.2 Acacia Pharma Business Overview
11.1.3 Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.1.4 Acacia Pharma Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.1.5 Acacia Pharma Recent Development
11.2 Church & Dwight
11.2.1 Church & Dwight Company Detail
11.2.2 Church & Dwight Business Overview
11.2.3 Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.2.4 Church & Dwight Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.2.5 Church & Dwight Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Hikma Pharmaceuticals
11.4.1 Hikma Pharmaceuticals Company Detail
11.4.2 Hikma Pharmaceuticals Business Overview
11.4.3 Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.4.4 Hikma Pharmaceuticals Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.4.5 Hikma Pharmaceuticals Recent Development
11.5 Lupin
11.5.1 Lupin Company Detail
11.5.2 Lupin Business Overview
11.5.3 Lupin Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.5.4 Lupin Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.5.5 Lupin Recent Development
11.6 OraCoat
11.6.1 OraCoat Company Detail
11.6.2 OraCoat Business Overview
11.6.3 OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.6.4 OraCoat Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.6.5 OraCoat Recent Development
11.7 Parnell Pharmaceuticals
11.7.1 Parnell Pharmaceuticals Company Detail
11.7.2 Parnell Pharmaceuticals Business Overview
11.7.3 Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.7.4 Parnell Pharmaceuticals Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.7.5 Parnell Pharmaceuticals Recent Development
11.8 Pendopharm
11.8.1 Pendopharm Company Detail
11.8.2 Pendopharm Business Overview
11.8.3 Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.8.4 Pendopharm Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.8.5 Pendopharm Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.9.4 Pfizer Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Detail
11.10.2 Sun Pharmaceutical Industries Business Overview
11.10.3 Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.10.4 Sun Pharmaceutical Industries Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.10.5 Sun Pharmaceutical Industries Recent Development
11.11 Synedgen
11.11.1 Synedgen Company Detail
11.11.2 Synedgen Business Overview
11.11.3 Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Introduction
11.11.4 Synedgen Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
11.11.5 Synedgen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Artificial Saliva
Table 3. Key Players of Salivary Stimulants
Table 4. Key Players of Saliva Substitutes
Table 5. Key Players of Drugs
Table 6. Key Players of Salivary Pens
Table 7. Key Players of Others
Table 8. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Region (2019-2024)
Table 12. Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Region (2025-2030)
Table 14. Xerostomia (Dry Mouth Disease) Therapeutics Market Trends
Table 15. Xerostomia (Dry Mouth Disease) Therapeutics Market Drivers
Table 16. Xerostomia (Dry Mouth Disease) Therapeutics Market Challenges
Table 17. Xerostomia (Dry Mouth Disease) Therapeutics Market Restraints
Table 18. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Players (2019-2024)
Table 20. Global Top Xerostomia (Dry Mouth Disease) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Xerostomia (Dry Mouth Disease) Therapeutics as of 2023)
Table 21. Ranking of Global Top Xerostomia (Dry Mouth Disease) Therapeutics Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Xerostomia (Dry Mouth Disease) Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Xerostomia (Dry Mouth Disease) Therapeutics Product Solution and Service
Table 25. Date of Enter into Xerostomia (Dry Mouth Disease) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share by Type (2019-2024)
Table 29. Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share by Type (2025-2030)
Table 31. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share by Application (2019-2024)
Table 33. Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share by Application (2025-2030)
Table 35. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 50. Acacia Pharma Company Detail
Table 51. Acacia Pharma Business Overview
Table 52. Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 53. Acacia Pharma Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 54. Acacia Pharma Recent Development
Table 55. Church & Dwight Company Detail
Table 56. Church & Dwight Business Overview
Table 57. Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 58. Church & Dwight Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 59. Church & Dwight Recent Development
Table 60. GlaxoSmithKline Company Detail
Table 61. GlaxoSmithKline Business Overview
Table 62. GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 63. GlaxoSmithKline Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 64. GlaxoSmithKline Recent Development
Table 65. Hikma Pharmaceuticals Company Detail
Table 66. Hikma Pharmaceuticals Business Overview
Table 67. Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 68. Hikma Pharmaceuticals Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 69. Hikma Pharmaceuticals Recent Development
Table 70. Lupin Company Detail
Table 71. Lupin Business Overview
Table 72. Lupin Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 73. Lupin Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 74. Lupin Recent Development
Table 75. OraCoat Company Detail
Table 76. OraCoat Business Overview
Table 77. OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 78. OraCoat Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 79. OraCoat Recent Development
Table 80. Parnell Pharmaceuticals Company Detail
Table 81. Parnell Pharmaceuticals Business Overview
Table 82. Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 83. Parnell Pharmaceuticals Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 84. Parnell Pharmaceuticals Recent Development
Table 85. Pendopharm Company Detail
Table 86. Pendopharm Business Overview
Table 87. Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 88. Pendopharm Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 89. Pendopharm Recent Development
Table 90. Pfizer Company Detail
Table 91. Pfizer Business Overview
Table 92. Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 93. Pfizer Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 94. Pfizer Recent Development
Table 95. Sun Pharmaceutical Industries Company Detail
Table 96. Sun Pharmaceutical Industries Business Overview
Table 97. Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 98. Sun Pharmaceutical Industries Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 99. Sun Pharmaceutical Industries Recent Development
Table 100. Synedgen Company Detail
Table 101. Synedgen Business Overview
Table 102. Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Product
Table 103. Synedgen Revenue in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024) & (US$ Million)
Table 104. Synedgen Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Artificial Saliva Features
Figure 4. Salivary Stimulants Features
Figure 5. Saliva Substitutes Features
Figure 6. Drugs Features
Figure 7. Salivary Pens Features
Figure 8. Others Features
Figure 9. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Application: 2023 VS 2030
Figure 11. Retail Pharmacies Case Studies
Figure 12. Hospital Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Xerostomia (Dry Mouth Disease) Therapeutics Report Years Considered
Figure 15. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Region: 2023 VS 2030
Figure 18. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Players in 2023
Figure 19. Global Top Xerostomia (Dry Mouth Disease) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Xerostomia (Dry Mouth Disease) Therapeutics as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Xerostomia (Dry Mouth Disease) Therapeutics Revenue in 2023
Figure 21. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Country (2019-2030)
Figure 23. United States Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Country (2019-2030)
Figure 27. Germany Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Region (2019-2030)
Figure 35. China Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Country (2019-2030)
Figure 43. Mexico Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Share by Country (2019-2030)
Figure 47. Turkey Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Xerostomia (Dry Mouth Disease) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Acacia Pharma Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 50. Church & Dwight Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 52. Hikma Pharmaceuticals Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 53. Lupin Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 54. OraCoat Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 55. Parnell Pharmaceuticals Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 56. Pendopharm Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 58. Sun Pharmaceutical Industries Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 59. Synedgen Revenue Growth Rate in Xerostomia (Dry Mouth Disease) Therapeutics Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
